6 research outputs found
Entropia Universitaria
En esta section se comunican las actividades de extension a la sociedadque actualmente lleva a cabo nuestro Departamento de Ciencias Exactase Ingenieria. Se dan a conocer tambien las actividades, convenios, cursos,talleres, seminarios, ciclos de conferencias, tesis de grado y cualquier otrainiciativa nacida en dicho departamento, que pueda ser de interes general
Entropfa Universitaria
En esta section se eomunican las aetividades de extension a la sociedadque actualmente lleva a cabo nuestro Departamento de Ciencias Exactase Ingenieria. Se dan a conocer tambien las aetividades, convenios, cursos,talleres, seminarios, ciclos de conferencias, tesis de grado y cualquier otrainiciativa nacida en dicho departamento, que pueda ser de interes general
EntropÃa Universitaria
En esta sección se comunican las actividades de extensión a la sociedadque actualmente lleva a cabo nuestro Departamento de Ciencias Exactase IngenierÃa. Se dan a conocer también las actividades, convenios, cursos,talleres, seminarios, ciclos de conferencias, tesis de grado y cualquier otrainiciativa nacida en dicho departamento, que pueda ser de interés general
The Virtual Laboratory: a toolset to enable distributed molecular modelling for drug design on the World-Wide Grid
Neuroscience instrumentation and distributed analysis of brain activity data: a case for eScience on global Grids
Everolimus in kidney transplant recipients at high cardiovascular risk: a narrative review.
Kidney transplant recipients (KTRs) are at increased risk of cardiovascular (CV) morbidity and mortality, and side effects induced by immunosuppressive therapy may be a major contributor to this risk, together with traditional CV risk factors. Many strategies have been considered in order to reduce CV risk in KTRs, such as steroid and/or calcineurin inhibitor (CNI) minimization, but current data are inconclusive. The introduction of mammalian target of rapamycin (mTOR) inhibitors, the cornerstone of CNI minimization, in the immunosuppressive protocol may reduce both the incidence and severity of CNI-associated side effects; however, whether this strategy has an impact on CV risk after kidney transplantation needs to be evaluated. To this end, a panel of Italian experts in the field of transplantation was convened in a series of meetings to assess the current literature on the potential of the mTOR inhibitor everolimus as a cardioprotective agent. This narrative review summarizes the panel's round-table discussions and provides recommendations for CV risk management in KTRs